SIC
AVBP icon

SJS Investment Consulting’s ArriVent BioPharma AVBP Stock Holding History

SJS Investment Consulting’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$938 Buy
+27
New +$797 ﹤0.01% 2052

Other funds holding AVBP

TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

SJS Investment Consulting's AVBP Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in ArriVent BioPharma (AVBP) in Q2 2026: 27 shares worth $938. The stake represents ﹤0.01% of the portfolio and ranks #2052 among its holdings.

20 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • SJS Investment Consulting held 27 shares of ArriVent BioPharma worth $938 as of Q2 2026.
  • ArriVent BioPharma was a new SJS Investment Consulting position in Q2 2026.
  • ArriVent BioPharma made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2052 holding.
  • 20 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.